ACE Report Cover
AAOS 2025: Efficacy of Autologous Dermal Fibroblast Injection - Retear Rate Post Rotator Cuff Repair
Language
Download
Cite
+ Favorites
Language
Download
Cite
+ Favorites
AceReport Image
SHOULDER & ELBOW
AAOS 2025: Efficacy of Autologous Dermal Fibroblast Injection - Retear Rate Post Rotator Cuff Repair .

Efficacy of autologous dermal fibroblast injection in reducing retear rate after arthroscopic rotator cuff repair: a prospective randomized controlled clinical trial

Seventy-two patients with full-thickness rotator cuff tears were randomized to receive either arthroscopic rotator cuff repair (ARCR) with intraoperative injection of autologous dermal fibroblasts (ADFs) (n=35) or ARCR alone (n=37). The primary outcome of interest was the retear rate assessed by MRI at 6 months postoperatively. Secondary outcomes included range of motion, ASES score, Constant score, and simple shoulder test (SST), evaluated at baseline, 6 months, and 12 months. Overall, the results of the study revealed a significantly lower retear rate in the ADF group compared to the control group (2.9% vs. 16.2%, p=0.012), although there were no significant differences in clinical outcomes between groups at follow-up. These findings suggest that ADF injection may enhance tendon healing after ARCR without compromising clinical recovery.

Unlock the Full ACE Report

You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or upgrade today and gain access to all OrthoEvidence
content for as little as $1.99 per week.
0 of 4 monthly FREE articles unlocked
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time.
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Translate ACE Report

OrthoEvidence utilizes a third-party translation service to make content accessible in multiple languages. Please note that while every effort is made to ensure accuracy, translations may not always be perfect.

Cite this ACE Report

OrthoEvidence. AAOS 2025: Efficacy of Autologous Dermal Fibroblast Injection - Retear Rate Post Rotator Cuff Repair. ACE Report. 2025;307(4):24. Available from: https://myorthoevidence.com/AceReport/Show/aaos-2025-efficacy-of-autologous-dermal-fibroblast-injection-retear-rate-post-rotator-cuff-repair

Copy Citation
Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Premium Member Feature

To access this feature, you must be logged into a premium OrthoEvidence account.

Share this ACE Report